Howe & Rusling Inc. Sells 29,784 Shares of AstraZeneca PLC (NASDAQ:AZN)

Howe & Rusling Inc. trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 19.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,812 shares of the company’s stock after selling 29,784 shares during the period. Howe & Rusling Inc.’s holdings in AstraZeneca were worth $9,335,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. McClarren Financial Advisors Inc. grew its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP purchased a new stake in AstraZeneca in the third quarter valued at $28,000. Pathway Financial Advisers LLC purchased a new stake in AstraZeneca in the 1st quarter valued at about $29,000. Finally, Hobbs Group Advisors LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at approximately $35,000. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen upped their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Performance

AZN opened at $63.80 on Wednesday. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The business’s 50 day moving average is $74.34 and its 200-day moving average is $78.06. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market cap of $197.82 billion, a PE ratio of 30.53, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the company posted $0.87 EPS. On average, analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.